Company Filing History:

4 out of 1,645

University of Utah Research Foundation

Univ. of Utah Research Foundation

5. 4 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2007

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7247436 - Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2007-07-24),

2. 6972176 - KVLQT1—a long QT syndrome gene (2005-12-06),

3. 6582913 - Diagnostic method for KVLQT1—a long QT syndrome gene (2003-06-24),

4. 6451534 - KVLQT1—a long QT syndrome gene (2002-09-17),

5. 6432644 - Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2002-08-13),

6. 6420124 - KVLQT1—a long qt syndrome gene (2002-07-16),

7. 6323026 - Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2001-11-27),

8. 6277978 - KVLQT1—a long QT syndrome gene (2001-08-21),

9. 6274332 - Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2001-08-14),

10. 6150357 - Potassium channel agonists (2000-11-21),

11. 5597818 - Methods of treating cardiac arrhythmia (1997-01-28),

12. 5428031 - Methods of treating cardiac arrhythmia (1995-06-27),

Title: The Innovations of Michael C Sanguinetti: Advancements in Long QT Syndrome Research

Introduction

Michael C Sanguinetti is an influential inventor and researcher residing in Salt Lake City, UT. With a remarkable portfolio of 12 patents, he has significantly contributed to the understanding and treatment of long QT syndrome, a critical cardiac condition. His work primarily focuses on the genetic aspects of this disorder, highlighting the importance of genomics in modern medical diagnostics.

Latest Patents

Among Michael's notable patents is the recent disclosure detailing mutations in the KCNE1 gene, which encodes for the human minK protein. This invention establishes KCNE1 as a gene associated with long QT syndrome. His patent includes comprehensive genomic structure data, specifically the sequence of the intron/exon junctions for the KVLQT1 and KCNE1 genes. This data is pivotal because it enables the design of primer pairs to amplify and sequence across the exons of these genes, facilitating the screening for mutations responsible for long QT syndrome. Furthermore, assays derived from this work allow for the identification of mutations in both DNA and proteins and pave the way for drug screening that may assist in treating or preventing long QT syndrome.

Career Highlights

Michael Sanguinetti has made significant strides in his career while working with reputable institutions, including the University of Utah Research Foundation. His research not only enhances the scientific community's understanding of genetic arrhythmia but also aims to translate these findings into practical screenings and therapeutic solutions for at-risk individuals.

Collaborations

Throughout his career, Sanguinetti has collaborated with eminent researchers, including Mark T Keating and Igor Splawski. These partnerships have proven invaluable in advancing research efforts related to cardiac genetics, further strengthening the impact of their collective findings in the field.

Conclusion

Michael C Sanguinetti's contributions to the realm of genetic research related to long QT syndrome are commendable. Through his innovative patents, he has established a solid foundation for future research, paving the way for improved diagnostics and treatments for those affected by this condition. His work exemplifies the crucial intersection of innovation and medicine, showcasing the vital role of inventors in advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com